[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.159.27. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Views 982
Citations 0
In This Issue of JAMA Neurology
August 2016

Highlights

JAMA Neurol. 2016;73(8):901. doi:10.1001/jamaneurol.2015.2473
Research

MacKenzie-Graham and colleagues study the association between localized gray matter (GM) atrophy and clinical disability in a biology-driven analysis of multiple sclerosis (MS). Magnetic resonance images were acquired from 133 women with relapsing-remitting MS and analyzed using voxel-based morphometry and volumetry. These biology-driven data indicate that specific disabilities in MS are associated with voxelwise GM loss in distinct locations. Editorial perspective is provided by Michael K. Racke, MD, and Jaime Imitola, MD.

Editorial

Boulouis et al determine whether hypodense regions, irrespective of their specific patterns, are associated with hematoma expansion in patients with intracerebral hemorrhage (ICH). They analyzed a large cohort of 784 patients with ICH, examined noncontrast computed tomography (NCCT) findings for any hypodensity, and replicated their findings on a different cohort of patients. They found that hypodensities within an acute ICH detected on an NCCT scan may predict hematoma expansion, independent of other clinical and imaging predictors. Editorial perspective is provided by Louis R. Caplan, MD.

Editorial

Clinical Review & Education

Walcott and colleagues summarize the clinical progression of flow diversion technology, from an experimental treatment to a commonly used method to treat large or complex aneurysms. Flow diversion is a treatment approved by the US Food and Drug Administration for brain aneurysms that redirects blood flow away from the aneurysm, thereby promoting growth of a new endothelial lining across the aneurysm opening. It is a disruptive technology that has changed the way many brain aneurysms are treated. Editorial perspective is provided by Babu G. Welch, MD, and H. Hunt Batjer, MD.

Editorial

Kang and Macdonald focus on the molecular pathogenic basis for genetic generalized epilepsies associated with mutations in the inhibitory γ-aminobutyric acid (GABAA) receptor γ2 subunit gene, GABRG2. Mutations in GABRG2 have been associated with simple febrile seizures and with genetic epilepsy syndromes, including childhood absence epilepsy, generalized epilepsy with febrile seizures plus, and Dravet syndrome or severe myoclonic epilepsy in infancy. They conclude that the epilepsy phenotypic heterogeneity associated with GABRG2 mutations may be related to the extent of the reduction of GABAA receptor channel function and the differential dominant negative suppression.

×